Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 72% · fresh
- Computed at
- 2026-07-21T07:33:03.644752+00:00
- Claimed
- 85
- Reported
- 77
- Verified
- 67
- Gap
- +18
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Growing
Decision
What the current evidence supports
Human editorial judgment · 2026-07-21
Proceed with caution
- Why
- It is genuinely first-in-class and already FDA-approved and commercially launching (82 sales reps in territory), but the approval is accelerated/conditional on a surrogate endpoint and the drug class has a documented high trial-failure rate, so durable clinical benefit is not yet proven.
- Next
- Track the ORIGIN 3 confirmatory eGFR/kidney-function readout and real-world uptake among the ~6,000 target U.S. nephrologists before upgrading readiness; re-check payer coverage decisions given the ~$425K/year list price.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 5
- Tier 1
- 1
- Tier 2
- 4
- Tier 3
- 0
- Supports
- 2
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-07-11
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-21 Reading moved from ready to ready.